Ausdal Financial Partners Inc. Purchases 10,262 Shares of Pfizer Inc. (NYSE:PFE)

Ausdal Financial Partners Inc. grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 66.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,658 shares of the biopharmaceutical company's stock after acquiring an additional 10,262 shares during the period. Ausdal Financial Partners Inc.'s holdings in Pfizer were worth $681,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Financial Engines Advisors L.L.C. bought a new position in Pfizer in the 4th quarter valued at $384,000. Summitry LLC bought a new position in shares of Pfizer in the fourth quarter valued at about $228,000. Murphy & Mullick Capital Management Corp acquired a new position in Pfizer during the 4th quarter worth about $235,000. Meiji Yasuda Asset Management Co Ltd. grew its holdings in Pfizer by 1.6% during the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 194,055 shares of the biopharmaceutical company's stock worth $5,148,000 after acquiring an additional 2,974 shares during the last quarter. Finally, PKS Advisory Services LLC acquired a new stake in Pfizer in the 4th quarter valued at about $324,000. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.

Remove Ads

Pfizer Stock Performance

NYSE PFE traded up $0.19 on Friday, hitting $25.20. 32,322,049 shares of the stock were exchanged, compared to its average volume of 39,037,478. The business's fifty day moving average is $26.06 and its 200 day moving average is $26.92. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a market capitalization of $142.93 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America reaffirmed a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Finally, UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.